Literature DB >> 15713351

The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.

A Gallagher1, P D Home.   

Abstract

A variety of abnormalities of metabolic, haemostatic and endothelial markers are associated with Type 2 diabetes. Evidence suggests that poor post-prandial blood glucose control may contribute to vascular risk. We aimed to examine whether the restoration of a more physiological insulin profile post-prandially would improve these abnormalities. Twenty-one patients with insulin-treated Type 2 diabetes were recruited into a single centre, crossover, double-blind study. Patients were randomized to unmodified human insulin or insulin aspart before main meals for 6-week study periods, both together with NPH insulin. At the end of each study period, pre-breakfast levels of markers of vascular risk were assessed and a test meal performed. There was no significant difference in HbA(1c) (7.04 +/- 0.13% (+/-S.E.) versus 7.15 +/- 0.11%, P = 0.060) with insulin aspart compared to human insulin at the end of each study period. The mean post-prandial blood glucose concentration at 90 min from self-monitored results was lower with insulin aspart than with human insulin (7.9 +/- 0.4 mmol/l versus 9.3 +/- 0.4 mmol/l, P = 0.011) as was study day post-prandial blood glucose at 90 min (8.4 +/- 0.5 mmol/l versus 9.2 +/- 0.6 mmol/l, P = 0.046). No significant differences were found in fasting lipid profile, apolipoproteins, fibrinogen, plasminogen activator inhibitor-1, E-selectin, or homocysteine between the two study periods. Insulin aspart resulted in improved post-prandial glycaemic control when compared to human insulin in Type 2 diabetic patients, but this was not associated with changes in markers of vascular risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713351     DOI: 10.1016/j.diabres.2004.07.010

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  8 in total

1.  Glucose information for tight glycemic control: different methods with different challenges.

Authors:  Christian Weber; Kurt Neeser
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

2.  Multifocal ERG defects associated with insufficient long-term glycemic control in adolescents with type 1 diabetes.

Authors:  Ekta Lakhani; Tom Wright; Mohamed Abdolell; Carol Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

3.  Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.

Authors:  Ulrike Hövelmann; Yaron Raiter; Anoop Chullikana; Mark Liu; Charles Donnelly; Tracey Lawrence; Nilanjan Sengupta; Gopu Cl; Gopinath Ranganna; Abhijit Barve
Journal:  Diabetes Obes Metab       Date:  2021-08-25       Impact factor: 6.408

4.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Authors:  Sumeet R Singh; Fida Ahmad; Avtar Lal; Changhua Yu; Zemin Bai; Heather Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

5.  1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes.

Authors:  Hannah Seok; Ji Hye Huh; Hyun Min Kim; Byung-Wan Lee; Eun Seok Kang; Hyun Chul Lee; Bong Soo Cha
Journal:  Diabetes Metab J       Date:  2015-03-09       Impact factor: 5.376

6.  Alleviating effects of lupeol on postprandial hyperglycemia in diabetic mice.

Authors:  Hyun-Ah Lee; Min-Jung Kim; Ji-Sook Han
Journal:  Toxicol Res (Camb)       Date:  2021-05-08       Impact factor: 3.524

Review 7.  Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.

Authors:  Steve Fordan; Philip Raskin
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

Review 8.  Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.

Authors:  Kjeld Hermansen; Mette Bohl; Anne Grethe Schioldan
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.